MCID: DRG003
MIFTS: 45

Drug Dependence

Categories: Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Drug Dependence

MalaCards integrated aliases for Drug Dependence:

Name: Drug Dependence 11 53 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:9974
ICD9CM 34 304.60
SNOMED-CT 68 191860009
UMLS 71 C0029792 C1510472

Summaries for Drug Dependence

Disease Ontology: 11 A substance dependence that involves the continued use of drugs despite problems related to use of the substance.

MalaCards based summary: Drug Dependence is related to polysubstance abuse and cannabis dependence. An important gene associated with Drug Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signal Transduction and GPCR downstream signalling. The drugs Buprenorphine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include prefrontal cortex, brain and cortex, and related phenotypes are nervous system and homeostasis/metabolism

Related Diseases for Drug Dependence

Diseases related to Drug Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 polysubstance abuse 32.4 DRD3 DRD2 CNR1
2 cannabis dependence 32.1 TTC12 DRD2 CNR1 ANKK1
3 hallucinogen dependence 32.0 TTC12 DRD2 CNR1 ANKK1
4 cocaine dependence 31.1 TTC12 SLC6A4 SLC6A3 POMC PDYN OPRM1
5 chronic pain 31.0 OPRM1 CNR1
6 opiate dependence 30.8 TTC12 SLC6A4 SLC6A3 POMC PNOC PENK
7 substance dependence 30.7 TTC12 SLC6A4 SLC6A3 POMC PDYN OPRM1
8 alcohol use disorder 30.7 SLC6A4 SLC6A3 POMC PDYN OPRM1 NPY
9 conduct disorder 30.7 SLC6A4 SLC6A3 POMC DRD2
10 antisocial personality disorder 30.5 SLC6A4 SLC6A3 DRD2 ANKK1
11 personality disorder 30.5 SLC6A4 SLC6A3 DRD3 DRD2 CRH ANKK1
12 morphine dependence 30.5 PENK PDYN OPRM1 OPRK1 OPRD1
13 acute stress disorder 30.3 SLC6A4 POMC CRH
14 generalized anxiety disorder 30.2 SLC6A4 POMC DRD2 CRH
15 social phobia 30.2 SLC6A4 SLC6A3 POMC DRD2 CRH
16 cannabis abuse 30.2 SLC6A4 DRD2 CNR1 ANKK1
17 borderline personality disorder 30.1 SLC6A4 SLC6A3 DRD2 CRH
18 sleep disorder 30.1 SLC6A4 SLC6A3 POMC NPY CRH
19 tobacco addiction 30.1 TTC12 SLC6A4 SLC6A3 PDYN OPRM1 DRD3
20 substance abuse 30.1 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
21 amenorrhea 30.0 POMC NPY CRH
22 migraine without aura 30.0 SLC6A4 DRD3 DRD2
23 cocaine abuse 30.0 SLC6A4 SLC6A3 PDYN OPRM1 OPRK1 DRD3
24 post-traumatic stress disorder 30.0 SLC6A4 SLC6A3 POMC NPY DRD2 CRH
25 opioid abuse 30.0 POMC PNOC PENK PDYN OPRM1 OPRL1
26 withdrawal disorder 30.0 SLC6A4 SLC6A3 POMC PNOC PENK PDYN
27 somatoform disorder 30.0 SLC6A4 POMC OPRM1 CRH
28 panic disorder 29.9 SLC6A4 SLC6A3 POMC NPY DRD3 DRD2
29 endogenous depression 29.8 SLC6A4 SLC6A3 POMC DRD2 CRH
30 epilepsy 29.8 SLC6A3 POMC PDYN OPRM1 NPY CNR1
31 psychotic disorder 29.8 SLC6A4 SLC6A3 PDYN OPRM1 NPY DRD3
32 body mass index quantitative trait locus 11 29.8 SLC6A3 POMC NPY DRD2 CRH CNR1
33 oppositional defiant disorder 29.8 SLC6A4 SLC6A3 DRD3 DRD2 ANKK1
34 bulimia nervosa 29.7 SLC6A4 SLC6A3 NPY DRD2 CNR1
35 alcohol dependence 29.7 TTC12 SLC6A4 SLC6A3 POMC PNOC PDYN
36 mood disorder 29.7 SLC6A4 SLC6A3 POMC PDYN NPY DRD3
37 anorexia nervosa 29.7 SLC6A4 POMC NPY DRD2 CRH CNR1
38 major depressive disorder 29.6 SLC6A4 SLC6A3 POMC PDYN OPRM1 NPY
39 heroin dependence 29.4 TTC12 SLC6A4 SLC6A3 PDYN OPRM1 OPRD1
40 attention deficit-hyperactivity disorder 29.4 TTC12 SLC6A4 SLC6A3 POMC PDYN OPRM1
41 obsessive-compulsive disorder 29.4 SLC6A4 SLC6A3 POMC PDYN NPY DRD3
42 pain agnosia 29.4 POMC PNOC PENK PDYN OPRM1 OPRL1
43 anxiety 29.3 SLC6A4 SLC6A3 POMC PNOC PDYN OPRM1
44 disease of mental health 29.3 SLC6A4 SLC6A3 POMC PDYN OPRM1 NPY
45 migraine with or without aura 1 29.3 SLC6A4 SLC6A3 POMC PNOC PDYN OPRM1
46 alzheimer disease, familial, 1 29.1 SLC6A4 SLC6A3 PDYN OPRM1 NPY DRD3
47 schizophrenia 28.6 SLC6A4 SLC6A3 POMC PNOC PDYN OPRM1
48 barbiturate dependence 11.1
49 prolactin producing pituitary tumor 10.4 POMC DRD2
50 barbiturate abuse 10.4 POMC OPRM1

Graphical network of the top 20 diseases related to Drug Dependence:



Diseases related to Drug Dependence

Symptoms & Phenotypes for Drug Dependence

GenomeRNAi Phenotypes related to Drug Dependence according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ACKR1 ANKK1 CHRM2 CNR1 CRH DRD2
2 no effect GR00402-S-2 10.19 ACKR1 ANKK1 CHRM2 CNR1 CRH DRD2

MGI Mouse Phenotypes related to Drug Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.28 CHRM2 CNR1 CRH DRD2 DRD3 NCAM1
2 homeostasis/metabolism MP:0005376 10.22 ACKR1 CHRM2 CNR1 CRH DRD2 DRD3
3 normal MP:0002873 10.11 CNR1 CRH DRD2 NPY OPRL1 OPRM1
4 growth/size/body region MP:0005378 10.07 CHRM2 CNR1 CRH DRD2 DRD3 NPY
5 no phenotypic analysis MP:0003012 10.03 CNR1 CRH DRD2 OPRD1 OPRM1 PDYN
6 adipose tissue MP:0005375 10.02 CNR1 CRH DRD2 DRD3 NPY OPRM1
7 behavior/neurological MP:0005386 9.89 CHRM2 CNR1 CRH DRD2 DRD3 NCAM1
8 digestive/alimentary MP:0005381 9.76 CNR1 DRD2 DRD3 NPY OPRK1 OPRM1
9 integument MP:0010771 9.47 CHRM2 CNR1 CRH DRD2 OPRD1 OPRK1

Drugs & Therapeutics for Drug Dependence

Drugs for Drug Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
4
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
7
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
8
Diamorphine Approved, Illicit, Investigational Phase 4 561-27-3 5462328
9
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
10 Sodium Channel Blockers Phase 4
11 Anesthetics, Local Phase 4
12 Anesthetics, Intravenous Phase 4
13 Anesthetics, General Phase 4
14 Anesthetics, Dissociative Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Diuretics, Potassium Sparing Phase 4
17 Analgesics, Opioid Phase 4
18 Analgesics Phase 4
19 Anticonvulsants Phase 4
20 Opiate Alkaloids Phase 4
21 Narcotic Antagonists Phase 4
22 Narcotics Phase 4
23 Buprenorphine, Naloxone Drug Combination Phase 4
24 Respiratory System Agents Phase 4
25 Antitussive Agents Phase 4
26 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
27
Ethanol Approved Phase 2, Phase 3 64-17-5 702
28
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
29
Gabapentin Approved, Investigational Phase 2, Phase 3 60142-96-3 3446
30
Clonidine Approved Phase 2, Phase 3 4205-91-8, 4205-90-7 2803 20179
31
Flumazenil Approved Phase 2, Phase 3 78755-81-4 3373
32
Metamfetamine Approved, Illicit, Withdrawn Phase 2, Phase 3 537-46-2 10836
33
Hydroxyzine Approved Phase 2, Phase 3 68-88-2 3658
34
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
35
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1, 1867-66-9 3821
36
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3 3680
38
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 3003 5743
39
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
40
Ketorolac Approved Phase 2, Phase 3 74103-06-3, 66635-83-4 3826
41
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
42
Ondansetron Approved, Withdrawn Phase 2, Phase 3 99614-02-5 4595
43
Succinylcholine Approved Phase 2, Phase 3 306-40-1, 71-27-2 5314
44
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
45
Probenecid Approved, Investigational Phase 2, Phase 3 57-66-9 4911
46
Benzoic acid Approved, Investigational Phase 2, Phase 3 65-85-0 243
47
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
48
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
49 Anti-Anxiety Agents Phase 2, Phase 3
50 Adrenergic alpha-Agonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Unknown status NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
2 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
3 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
4 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
5 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
6 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
7 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
8 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
9 Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models Completed NCT00876941 Phase 3
10 Improving Treatment Outcomes for Prescription Opioid Dependence Completed NCT02543944 Phase 2, Phase 3 Gabapentin;Buprenorphine;Clonidine;Naltrexone (oral);Naltrexone (depot);Placebo
11 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
12 Double-Blind, Placebo Controlled Trial of Prometa Pharmacotherapy for the Treatment of Methamphetamine Abuse Completed NCT00260481 Phase 2, Phase 3 Prometa;Placebo
13 Making Alcoholics Anonymous Easier: A Group TSF Approach Completed NCT01382316 Phase 3
14 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
15 Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient Recruiting NCT03367988 Phase 2, Phase 3 Opioid Anesthesia;Opioid-free Anesthesia
16 Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal in People With Chronic Pain Undergoing Voluntary Opioid Tapering: a Pilot Study Not yet recruiting NCT04939623 Phase 2, Phase 3 Probenecid
17 HIV Prevention Partnership in Russian Alcohol Treatment Completed NCT00183118 Phase 1, Phase 2
18 Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Completed NCT01246401 Phase 1, Phase 2 Extended-Release Naltrexone
19 Effectiveness of Extended Treatment for Drug Dependence - City Supplement Completed NCT01153464 Phase 2
20 Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone Recruiting NCT04003948 Phase 2 Ibogaine Hydrochloride
21 Drug Discrimination in Methadone-Maintained Humans Study 1 Completed NCT00593463 Phase 1 Cycloserine;Diltiazem;Gabapentin;Isradipine;Naloxone;Nifedipine;Placebo;Verapamil
22 Drug Discrimination in Methadone-Maintained Humans Study 3 Completed NCT01068847 Phase 1 2-4 of the drugs listed below
23 Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder Completed NCT00218725 Phase 1
24 Cracking Addiction: Does BRAIN Stimulation-induced Neuroplasticity Reverse Prefrontal Cortex Hypoactivity in Cocaine and neW stImulanTs addiCtion in Humans? (BRAIN SWITCH) Unknown status NCT03333460
25 Impact of Group Motivational Interviewing for Dually Diagnosed Veterans Completed NCT00706901
26 The Effectiveness of a Novel Psychosocial Intervention "Programme d'Aide au Succès du Sevrage " (PASSE-65+) Designed to Help Older Benzodiazepine Users to Gradually Wean Their Medication Completed NCT02281175
27 Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification Completed NCT03694327
28 The Use of Chemsex (Drug Use in a Sexual Context) Among MSM (Men Who Have Sex With Men) and Transgender People in France, Whether or Not Taking PrEP, and Its Impact on PrEP Adherence Completed NCT04709016
29 Enhancing the Role of Commune Health Workers in HIV and Drug Control: A Randomized Controlled Trial Completed NCT02130921
30 Collaborative Care Intervention to Improve Providers' Opioid Prescribing for HIV-infected Patients - Intervention Component Completed NCT02564341
31 Automated Recovery Line for Medication Assisted Treatment Completed NCT02124980
32 A Randomized Trial of CBT4CBT for Women in Residential Treatment for Substance Use Disorders Completed NCT03678051
33 Clinical Trial of Mobile-Based Intervention for Smoking Cessation Completed NCT02656745
34 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550
35 Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation Completed NCT01052675
36 Automatic Versus Evaluative Components of Cue Reactivity Completed NCT01036126
37 Brain Activation in Response to Motivational and Affective Stimuli: Pharmacological Manipulations Completed NCT00047866
38 Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) Completed NCT00579267
39 Behavioral Economics of Human Drug Self-Administration Completed NCT00005765 nicotine;alcohol
40 The Effect of Fetal Gender on Maternal Substance Abuse Treatment Completed NCT00882648
41 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 buprenorphine
42 Collaborative Care Intervention to Improve Providers' Opioid Prescribing for HIV-infected Patients - Patient Cohort Component Completed NCT02525731
43 Improving Longterm SUD Outcomes With Telephone Case Monitoring Completed NCT00265512
44 A Prospective Assessment of Opioid Utilization Post-operatively in Sports Orthopaedic Surgeries Completed NCT03422211
45 Evaluation of the Effects of a Drug With Fiscalized Substances Dispensation, Health Education and Pharmacovigilance Continuing Education Program in Community Pharmacies: Study Protocol for a Multicenter, Cluster-randomized Controlled Trial Completed NCT03388567
46 Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits Completed NCT01171677
47 HIV, Buprenorphine, and the Criminal Justice System Completed NCT01550341 Buprenorphine/naloxone;Placebo Oral Tablet
48 Integrated Treatment of Operation Enduring Freedom/Operation Iraqi Freedom Veterans With Post-traumatic Stress Disorder and Substance Use Disorders Completed NCT01338506
49 Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks Completed NCT02224508
50 Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User: Results of the Randomized Controlled Trial Completed NCT02173041

Search NIH Clinical Center for Drug Dependence

Genetic Tests for Drug Dependence

Anatomical Context for Drug Dependence

Organs/tissues related to Drug Dependence:

MalaCards : Prefrontal Cortex, Brain, Cortex, Amygdala, Subthalamic Nucleus, Cingulate Cortex, Spinal Cord

Publications for Drug Dependence

Articles related to Drug Dependence:

(show top 50) (show all 4001)
# Title Authors PMID Year
1
Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2) with nicotine addiction. 53 62
19644963 2010
2
The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. 53 62
19359525 2009
3
Peptide kappa opioid receptor ligands: potential for drug development. 53 62
19430912 2009
4
Interaction between two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication study in family-based sample and population-based sample. 53 62
19052543 2009
5
Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. 53 62
18828801 2008
6
A role for brain stress systems in addiction. 53 62
18614026 2008
7
Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence. 53 62
17910740 2008
8
The opioid system in alcohol and drug dependence: family-based association study. 53 62
17503481 2007
9
Alcohol dependence with comorbid drug dependence: genetic and phenotypic associations suggest a more severe form of the disorder with stronger genetic contribution to risk. 53 62
17567401 2007
10
Dopamine D3 receptor ligands for the treatment of tobacco dependence. 53 62
17155853 2007
11
11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. 53 62
17015906 2006
12
[How do self-help agencies work for recovery of drug dependence in Japan?]. 53 62
17037343 2006
13
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. 53 62
16476706 2006
14
The dopamine D3 receptor and drug dependence: effects on reward or beyond? 53 62
15963538 2005
15
Allelic association of a dopamine transporter gene polymorphism with antisocial behaviour in heroin-dependent patients. 53 62
16109590 2005
16
CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. 53 62
16000316 2005
17
How individual sensitivity to opiates can be predicted by gene analyses. 53 62
15925706 2005
18
Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. 53 62
15542743 2004
19
Analysis of monoamine oxidase A (MAO-A) promoter polymorphism in male heroin-dependent subjects: behavioural and personality correlates. 53 62
15088154 2004
20
[A study on effectiveness of recovery from drug dependence by participates with "DARC"]. 53 62
15160890 2004
21
Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. 53 62
12786988 2003
22
Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. 53 62
11526463 2001
23
Family-based study of DRD2 alleles in alcohol and drug dependence. 53 62
11054774 2000
24
[A study of recovery factor about drug addiction recovery center "DARC"]. 53 62
11019561 2000
25
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 53 62
9756053 1998
26
Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? 53 62
9693390 1998
27
Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. 53 62
9702742 1998
28
Enhanced stimulatory adenylyl cyclase signaling during opioid dependence is associated with a reduction in palmitoylated Gs alpha. 53 62
9415709 1997
29
Mu opioid receptor gene variants: lack of association with alcohol dependence. 53 62
9399694 1997
30
The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. 53 62
8845863 1996
31
Association and linkage studies of the TAQI A1 allele at the dopamine D2 receptor gene in samples of female and male alcoholics. 53 62
7485259 1995
32
Genetic variation in fatty acid amide hydrolase (FAAH): Associations with early drinking and smoking behaviors. 62
36403489 2023
33
Compulsive drug-taking is associated with habenula-frontal cortex connectivity. 62
36469769 2022
34
Effect of Amoxicillin/Clavulanic acid in attenuating Pregabalin-induced Condition Place Preference. 62
36470419 2022
35
[Burnout and dependence among medical personnel timeless and during the COVID-19 pandemic, using surgery and anesthesia as examples]. 62
35737018 2022
36
Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice. 62
36179506 2022
37
Effects of Aerobic Exercise on Markers of Brain Injury in Methamphetamine-Dependent Individuals: A Randomized Controlled Trial. 62
36358447 2022
38
Neural signaling of methamphetamine craving and seeking intensified by bupropion in the ventral tegmental area-cortico-accumbens circuitry in mice. 62
36301216 2022
39
A high-fat diet has sex-specific effects on nicotine vapor self-administration in mice. 62
36402049 2022
40
Sustained reduction of attentional bias to smoking cues by smartphone-delivered attentional bias modification training for smokers. 62
35025555 2022
41
Twenty-year trends in pharmaceutical fentanyl and illicit fentanyl deaths, Australia 2001-2021. 62
36150355 2022
42
Astroglial Knockout of Glucocorticoid Receptor Attenuates Morphine Withdrawal Symptoms, but Not Antinociception and Tolerance in Mice. 62
33821329 2022
43
Ultrasound-augmented anti-inflammatory exosomes for targeted therapy in rheumatoid arthritis. 62
36070446 2022
44
Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain. 62
36283655 2022
45
α2δ-1 protein drives opioid-induced conditioned reward and synaptic NMDA receptor hyperactivity in the nucleus accumbens. 62
36222452 2022
46
The potent α2-adrenoceptor antagonist RS 79948 also inhibits dopamine D2 -receptors: Comparison with atipamezole and raclopride. 62
35850212 2022
47
Analytical strategies in neurotransmitter measurements: A mini literature review. 62
36251619 2022
48
Preparedness for healthy ageing and polysubstance use in long-term cannabis users: a population-representative longitudinal study. 62
36202130 2022
49
Is IIIG9 a New Protein with Exclusive Ciliary Function? Analysis of Its Potential Role in Cancer and Other Pathologies. 62
36291193 2022
50
Leukocyte telomere length is not shortened in methamphetamine dependence or methamphetamine-induced psychosis but is increased following traumatic events. 62
34895035 2022

Variations for Drug Dependence

Expression for Drug Dependence

Search GEO for disease gene expression data for Drug Dependence.

Pathways for Drug Dependence

GO Terms for Drug Dependence

Cellular components related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.71 ACKR1 CHRM2 CNR1 DRD2 DRD3 NCAM1
2 membrane GO:0016020 10.71 ACKR1 CHRM2 CNR1 DRD2 DRD3 NCAM1
3 plasma membrane GO:0005887 10.54 CHRM2 CNR1 DRD2 DRD3 OPRD1 OPRK1
4 plasma membrane GO:0005886 10.54 CHRM2 CNR1 DRD2 DRD3 OPRD1 OPRK1
5 dendrite GO:0030425 10.32 CHRM2 DRD2 OPRK1 OPRM1 PDYN PENK
6 neuron projection GO:0043005 10.28 SLC6A4 SLC6A3 OPRM1 OPRL1 OPRK1 OPRD1
7 neuronal cell body GO:0043025 10.27 SLC6A3 PNOC PENK PDYN OPRK1 CRH
8 membrane raft GO:0045121 10.25 SLC6A4 SLC6A3 OPRM1 OPRD1 CNR1
9 perikaryon GO:0043204 10.21 PENK OPRM1 OPRK1 NPY DRD2
10 synapse GO:0045202 10.21 CHRM2 CNR1 CRH DRD2 DRD3 OPRK1
11 GABA-ergic synapse GO:0098982 10.07 CNR1 DRD2 DRD3 NPY
12 postsynaptic membrane GO:0045211 9.92 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 DRD2
13 neuronal dense core vesicle GO:0098992 9.89 PDYN OPRD1 NPY
14 symmetric synapse GO:0032280 9.86 PENK CHRM2
15 axon terminus GO:0043679 9.86 SLC6A3 PNOC PENK PDYN OPRK1 OPRD1
16 presynaptic membrane GO:0042734 9.85 CHRM2 CNR1 DRD2 OPRD1 OPRK1 OPRM1
17 spine apparatus GO:0097444 9.84 OPRM1 OPRD1
18 obsolete integral component of postsynaptic membrane GO:0099055 9.73 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2 CHRM2
19 obsolete integral component of presynaptic membrane GO:0099056 9.23 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 DRD2

Biological processes related to Drug Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.43 ACKR1 CHRM2 CNR1 DRD2 DRD3 OPRD1
2 signal transduction GO:0007165 10.41 POMC PNOC PENK OPRM1 OPRL1 OPRK1
3 chemical synaptic transmission GO:0007268 10.36 CHRM2 CRH NPY OPRK1 PDYN PENK
4 aging GO:0007568 10.29 CNR1 NPY PENK SLC6A3
5 locomotory behavior GO:0007626 10.2 SLC6A3 PENK OPRK1 DRD3 DRD2
6 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 10.19 OPRM1 OPRK1 OPRD1
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 10.19 OPRM1 OPRD1 NPY CNR1 CHRM2
8 response to nicotine GO:0035094 10.16 SLC6A3 PENK DRD2 CNR1
9 sensory perception of pain GO:0019233 10.16 CNR1 OPRK1 OPRL1 OPRM1 PENK
10 response to radiation GO:0009314 10.13 PENK OPRM1 OPRK1
11 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 10.13 OPRM1 OPRL1 OPRK1 OPRD1
12 eating behavior GO:0042755 10.13 OPRM1 OPRL1 OPRK1 OPRD1
13 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 10.12 OPRL1 DRD3 DRD2
14 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 10.1 CHRM2 CNR1 DRD2
15 negative regulation of blood pressure GO:0045776 10.1 OPRL1 NPY DRD3 DRD2 CNR1
16 negative regulation of voltage-gated calcium channel activity GO:1901386 10.09 OPRL1 DRD3 DRD2
17 estrous cycle GO:0044849 10.08 OPRM1 OPRL1 OPRK1
18 behavioral response to cocaine GO:0048148 10.08 DRD2 DRD3 OPRK1
19 regulation of sensory perception of pain GO:0051930 10.08 OPRD1 OPRK1 OPRL1 OPRM1
20 response to ethanol GO:0045471 10.06 SLC6A3 PENK OPRM1 OPRK1 DRD3 DRD2
21 prepulse inhibition GO:0060134 10.05 SLC6A3 DRD3 DRD2
22 negative regulation of synaptic transmission, glutamatergic GO:0051967 10.01 DRD3 DRD2
23 negative regulation of cytosolic calcium ion concentration GO:0051481 10.01 DRD3 DRD2
24 behavioral response to ethanol GO:0048149 10.01 OPRM1 DRD2
25 monoamine transport GO:0015844 10 SLC6A4 SLC6A3
26 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 10 DRD3 DRD2
27 adenohypophysis development GO:0021984 10 SLC6A3 DRD2
28 adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway GO:0007197 10 OPRM1 CHRM2
29 response to cocaine GO:0042220 10 CNR1 DRD2 DRD3 OPRK1 OPRM1 SLC6A3
30 hyaloid vascular plexus regression GO:1990384 9.99 SLC6A3 DRD2
31 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.99 OPRM1 OPRL1
32 dopamine uptake involved in synaptic transmission GO:0051583 9.98 SLC6A3 DRD2
33 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.98 DRD2 DRD3
34 negative regulation of dopamine secretion GO:0033602 9.97 CNR1 DRD2
35 regulation of potassium ion transport GO:0043266 9.97 DRD2 DRD3
36 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.97 DRD2 DRD3
37 synaptic transmission, dopaminergic GO:0001963 9.97 CRH DRD2 DRD3
38 G protein-coupled opioid receptor signaling pathway GO:0038003 9.97 OPRD1 OPRK1 OPRL1 OPRM1
39 positive regulation of appetite GO:0032100 9.96 NPY OPRM1
40 positive regulation of eating behavior GO:1904000 9.96 NPY OPRK1
41 conditioned place preference GO:1990708 9.96 OPRK1 OPRL1
42 response to histamine GO:0034776 9.94 DRD2 DRD3
43 acid secretion GO:0046717 9.94 DRD2 DRD3
44 regulation of locomotion involved in locomotory behavior GO:0090325 9.93 DRD3 DRD2
45 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.92 OPRM1 OPRK1
46 neuropeptide signaling pathway GO:0007218 9.91 NPY OPRD1 OPRK1 OPRL1 OPRM1 PDYN
47 response to morphine GO:0043278 9.9 PENK OPRM1 OPRK1 DRD3 DRD2 CNR1
48 regulation of synaptic vesicle exocytosis GO:2000300 9.85 NPY DRD2 CHRM2
49 synaptic signaling via neuropeptide GO:0099538 9.81 PENK NPY
50 regulation of biological quality GO:0065008 9.71 DRD3 DRD2

Molecular functions related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 10.01 OPRM1 OPRL1 OPRK1 OPRD1
2 neuropeptide binding GO:0042923 9.97 OPRM1 OPRL1 OPRK1 OPRD1
3 G protein-coupled receptor activity GO:0004930 9.93 ACKR1 CHRM2 CNR1 DRD2 DRD3 NPY
4 neuropeptide hormone activity GO:0005184 9.92 CRH NPY PENK PNOC
5 monoamine transmembrane transporter activity GO:0008504 9.81 SLC6A4 SLC6A3
6 dopamine binding GO:0035240 9.8 SLC6A3 DRD2
7 receptor serine/threonine kinase binding GO:0033612 9.78 OPRK1 OPRD1
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.73 DRD3 DRD2
9 opioid receptor binding GO:0031628 9.73 PNOC PENK PDYN
10 opioid peptide activity GO:0001515 9.63 PNOC PENK PDYN
11 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD3 DRD2
12 G protein-coupled opioid receptor activity GO:0004985 9.1 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Drug Dependence

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....